<DOC>
	<DOCNO>NCT00034541</DOCNO>
	<brief_summary>The study enroll approximately 33 EGFr positive chemotherapy-naive stage IV non-small cell lung cancer patient . Patients receive cetuximab combination carboplatin paclitaxel two cycle disease progression patient exhibit intolerable toxicity . Patients evaluate efficacy safety throughout duration study .</brief_summary>
	<brief_title>Study Cetuximab Combination With Carboplatin-Paclitaxel Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>The study enroll approximately 33 chemotherapy-naive stage IV non-small cell lung cancer patient . Patients receive 3-week cycle therapy exception initial cycle patient receive 4 cycle therapy . Patients enrol EGFr expression confirm study inclusion exclusion criterion meet . An initial dose cetuximab administer prior initiation chemotherapy . Thereafter , cetuximab infused weekly . On first day cycle , paclitaxel infusion administer post completion cetuximab infusion , immediately follow carboplatin infusion . Patients receive cetuximab combination carboplatin paclitaxel two cycle disease progression patient exhibit intolerable toxicity . Patients evaluate tumor response end every two cycle therapy evaluate safety throughout study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>The following inclusion criterion must meet : The patient stage IV NSCLC either present prior histologic pathologic confirmation NSCLC The patient unidimensionally measurable stage IV NSCLC The patient chemotherapynaive stage IV NSCLC . The patient may recurrent disease prior radiation therapy receive . Pathological confirmation recurrence require disease within radiation portal . The patient 's ECOG performance status ≤ 2 study entry . The patient immunohistochemical evidence EGFr expression ( ≥1+ ) . Patients tumor tissue available EGFr test undergo biopsy accessible tumor . EGFr expression must confirm prior study entry . The patient give sign informed consent . The patient 18 year age old . The patient adequate hematologic function , define absolute neutrophil ( ANC ) ≥ 1,500/mL3 , WBC count≥3,000/mL3 , platelet count ≥100,000/mL3 , hemoglobin level ≥9g/dL . The patient adequate hepatic function define total bilirubin level ≤1.5 X upper limit normal ( ULN ) alkaline phosphatase , AST , ALT level ≤2.5 X ULN . The patient adequate renal function serum creatinine level ≤1.5 mg/dL creatinine clearance ≥60 cc/minute . The patient disease free previously treat malignancy , disease study , great 3 year ( patient history previous basal cell carcinoma skin preinvasive carcinoma cervix exclude ) . The patient , woman , agree use effective contraception childbearing potential exists . The patient , man , agree use effective contraception . The following ten exclusion criterion study : The patient receive prior cetuximab therapy . The patient disease amenable curative surgery . The patient receive prior chemotherapy disease study . The patient receive wide field radiation therapy within 4 week prior first infusion cetuximab . The patient may local irradiation management tumorrelated symptom . The patient undergone major thoracic abdominal surgery within 30 day ( allow full recovery ) prior first infusion cetuximab . The patient history uncontrolled angina , arrhythmia , congestive heart failure . The patient uncontrolled seizure disorder , active neurological disease ( tumor relate ) , grade ≥2 neuropathy ( patient meningeal central nervous system [ CNS ] involvement tumor eligible ) . The patient history hypersensitivity Cremophor EL . The patient , woman , pregnant ( confirm serum BHCG ) breastfeeding . The patient receive investigation agent within 30 day study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>cetuximab</keyword>
	<keyword>epidermal growth factor receptor</keyword>
	<keyword>antibody</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>carboplatin</keyword>
	<keyword>paclitaxel</keyword>
</DOC>